"pancreatic tumor progression" trang 3 - tải miễn phí từ tailieunhanh
Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: A single center experience

Incorporating Yttrium-90 trans-arterial radioembolization (TARE) in the treatment of metastatic pancreatic adenocarcioma: A single center experience
7    72    1
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice

NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice
8    64    1
The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1

The anti-oxidative transcription factor Nuclear factor E2 related factor-2 (Nrf2) counteracts TGF-β1 mediated growth inhibition of pancreatic ductal epithelial cells -Nrf2 as determinant of pro-tumorigenic functions of TGF-β1
14    69    1
Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2

Establishment and characterization of new cell lines of anaplastic pancreatic cancer, which is a rare malignancy: OCUP-A1 and OCUP-A2
13    48    1
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine
12    30    1
Small nucleolar RNA U91 is a new internal control for accurate microRNAs quantification in pancreatic cancer

Small nucleolar RNA U91 is a new internal control for accurate microRNAs quantification in pancreatic cancer
10    43    1
Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model
14    39    1
Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma

Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma
11    41    1
SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells

SMAD4 Loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells
14    33    1
GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: Immunohistochemistry study showing the correlation between expression and survival

GLUT-1 as a predictor of worse prognosis in pancreatic adenocarcinoma: Immunohistochemistry study showing the correlation between expression and survival
9    33    1
Effects of insulin on human pancreatic cancer progression modeled in vitro

Effects of insulin on human pancreatic cancer progression modeled in vitro
12    52    1
Epithelial Notch signaling is a limiting step for pancreatic carcinogenesis

Epithelial Notch signaling is a limiting step for pancreatic carcinogenesis
11    24    1
Survival in overweight patients with advanced pancreatic carcinoma: A multicentre cohort study

Survival in overweight patients with advanced pancreatic carcinoma: A multicentre cohort study
7    64    1
Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma

Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma
10    58    1
IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer

IGF-1 receptor and IGF binding protein-3 might predict prognosis of patients with resectable pancreatic cancer
9    31    1
The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: An immunohistochemical study of tissue microarrays

The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: An immunohistochemical study of tissue microarrays
10    60    1
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma

High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma
12    59    1
Malignant extra-adrenal pancreatic paraganglioma: Case report and literature review

Malignant extra-adrenal pancreatic paraganglioma: Case report and literature review
5    60    1
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: A single-institution retrospective analysis

Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: A single-institution retrospective analysis
10    50    1
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma

A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma
8    37    1